XML 38 R25.htm IDEA: XBRL DOCUMENT v3.4.0.3
Balance Sheet Account Detail (Tables)
 3 Months Ended
Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Cash And Cash Equivalent Marketable Securities Unrealized Gain Table
The following is a summary of our “cash and cash equivalents” and “marketable securities”:
 
 
 
 
 
 
 
 
 
 
Marketable Securities
 
Cost
 
Gross
Unrealized
Gains
 
Gross
Unrealized
Losses
 
Estimated
Fair
Value
 
Cash and Cash
Equivalents
 
Current
 
Long
Term
March 31, 2016
 
 
 
 
 
 
 
 
 
 
 
 
 
Bank deposits
$
52,160

 
$
—

 
$
—

 
$
52,160

 
$
52,160

 
$
—

 
$
—

Money market funds
80,146

 
—

 
—

 
80,146

 
80,146

 
—

 
—

Bank certificates of deposits
246

 
—

 
—

 
246

 
—

 
246

 
—

Mutual funds
—

 
—

 
—

 
—

 
—

 
—

 
—

Total cash and equivalents and marketable securities
$
132,552

 
$
—

 
$
—

 
$
132,552

 
$
132,306

 
$
246

 
$
—

December 31, 2015
 
 
 
 
 
 
 
 
 
 
 
 
 
Bank deposits
$
59,625

 
$
—

 
$
—

 
$
59,625

 
$
59,625

 
$
—

 
$
—

Money market funds
80,116

 
—

 
—

 
80,116

 
80,116

 
—

 
—

Bank certificates of deposits
245

 
—

 
—

 
245

 
—

 
245

 
—

Mutual funds
—

 
—

 
—

 
—

 
—

 
—

 
—

Total cash and equivalents and marketable securities
$
139,986

 
$
—

 
$
—

 
$
139,986

 
$
139,741

 
$
245

 
$
—
Schedule of Property and Equipment Net of Accumulated Depreciation
“Property and equipment, net of accumulated depreciation” consist of the following: 
 
March 31, 2016
 
December 31, 2015
Computer hardware and software
$
3,824

 
$
3,785

Laboratory equipment
622

 
608

Office furniture
355

 
355

Leasehold improvements
2,880

 
2,872

Property and equipment, at cost
7,681

 
7,620

(Less): Accumulated depreciation
(6,871
)
 
(6,702
)
Property and equipment, net of accumulated depreciation
$
810

 
$
918
Components of Inventories
“Inventories” consist of the following: 
 
March 31, 2016
 
December 31, 2015
Raw materials
$
1,782

 
$
1,606

Work-in-process*
7,457

 
4,228

Finished goods
839

 
1,498

(Less:) Non-current portion of inventories included within "other assets" **
(6,923
)
 
(3,156
)
Inventories
$
3,155

 
$
4,176


* In January 2016, we received $3.4 million of ZEVALIN antibody materials for its future manufacture (representing strategic long-term supply).

** The "non-current" portion of inventories is presented within "other assets" in the accompanying Condensed Consolidated Balance Sheet at March 31, 2016. This value of $6.9 million represents product that we expect to sell beyond March 31, 2017.
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure
“Prepaid expenses and other assets” consist of the following:
 
March 31, 2016
 
December 31, 2015
Prepaid operating expenses
$
2,352

 
$
3,507

Current portion of debt issuance costs*
—

 
—

Prepaid expenses and other assets
$
2,352

 
$
3,507

* Beginning January 1, 2016, our debt issuance costs (current and non-current portions) were retrospectively reclassified from “prepaid expenses and other assets” and "other assets" to a reduction of the carrying amount of “convertible senior notes” (i.e., contra-liability - see Note 14) within our accompanying Consolidated Balance Sheets, in accordance with the FASB-issued Accounting Standards Update 2015-03, Simplifying the Presentation of Debt Issuance Costs (“ASU 2015-03”). These amounts were $2.0 million and $2.2 million (including current and non-current portions) as of March 31, 2016 and December 31, 2015, respectively.
Schedule of Other Receivables
“Other receivables” consist of the following:
 
March 31, 2016
 
December 31, 2015
Income tax receivable
$
754

 
$
1,301

Insurance receivable
7,188

 
7,100

Mundipharma promissory note
2,347

 
2,215

CASI note - short term*
1,500

 
—

Eagle service revenue and support costs
1,450

 
—

Research and development expenses - reimbursements due
1,617

 
1,699

Other miscellaneous receivables
319

 
257

Other receivables
$
15,175

 
$
12,572

* This full balance was prospectively reclassified as of March 31, 2016 to "other receivables" (presented within current assets on the accompanying Condensed Consolidated Balance Sheets) from "other assets" (presented within non-current assets) due to this note's maturity date of March 17, 2017 (i.e., within 12 months of March 31, 2016) - see Note 10.
Components of Intangible Assets Net of Accumulated Amortization
“Intangible assets, net of accumulated amortization and impairment charges” consist of the following: 
 
 
 
March 31, 2016
 
Historical
Cost
 
Accumulated
Amortization
 
Foreign
Currency
Translation
 
Impairment
 
Net Amount
 
Full
Amortization
Period
(months)
 
Remaining
Amortization
Period
(months)
MARQIBO IPR&D (NHL and other novel indications)
$
17,600

 
$
—

 
$
—

 
$
—

 
$
17,600

 
n/a
 
n/a
EVOMELA distribution rights (1)
7,700

 
—

 
—

 
—

 
7,700

 
156
 
156
BELEODAQ distribution rights
25,000

 
(3,281
)
 
—

 
—

 
21,719

 
160
 
139
MARQIBO distribution rights
26,900

 
(9,624
)
 
—

 
—

 
17,276

 
81
 
48
FOLOTYN distribution rights
118,400

 
(31,834
)
 
—

 
—

 
86,566

 
152
 
110
ZEVALIN distribution rights – U.S.
41,900

 
(31,477
)
 
—

 
—

 
10,423

 
123
 
36
ZEVALIN distribution rights – Ex-U.S.
23,490

 
(13,543
)
 
(3,566
)
 
—

 
6,381

 
96
 
48
FUSILEV distribution rights (2)
16,778

 
(9,618
)
 
—

 
(7,160
)
 
—

 
56
 
0
FOLOTYN out-license (3)
27,900

 
(9,789
)
 
—

 
(1,023
)
 
17,088

 
110
 
76
Total intangible assets
$
305,668

 
$
(109,166
)
 
$
(3,566
)
 
$
(8,183
)
 
$
184,753

 
 
 
 
 
(1)
The FDA approval of EVOMELA in March 2016 triggered a $6 million payment due to CyDex Pharmaceuticals, Inc. (a wholly-owned subsidiary of Ligand Pharmaceuticals Incorporated). This event also resulted in a reclassification of our $7.7 million "EVOMELA IPR&D" to "EVOMELA distribution rights" due to our ability to begin its commercialization with this FDA approval. In accordance with our capitalization policy for intangible assets, amortization will commence on the first day of the following month of this reclassification (i.e., April 1, 2016).

(2)
On February 20, 2015, the U.S. District Court for the District of Nevada found the patent covering FUSILEV to be invalid, which was upheld on appeal. On April 24, 2015, Sandoz began to commercialize a generic version of FUSILEV. This represented a “triggering event” under applicable GAAP in evaluating the value of our FUSILEV distribution rights as of March 31, 2015, resulting in a $7.2 million impairment charge (non-cash) in the first quarter of 2015. We accelerated amortization expense recognition in 2015 for the remaining net book value of FUSILEV distribution rights.

(3)
On May 29, 2013, we amended our FOLOTYN collaboration agreement with Mundipharma. As a result of the amendment, Europe and Turkey were excluded from Mundipharma’s commercialization territory, and their royalty rates and milestone payments to us were modified. This constituted a change under which we originally valued the FOLOTYN out-license as part of business combination accounting, resulting in an impairment charge (non-cash) of $1.0 million in the second quarter of 2013.

 
 
 
December 31, 2015

Historical
Cost
 
Accumulated
Amortization
 
Foreign
Currency
Translation
 
Impairment
 
Net Amount
MARQIBO IPR&D (NHL and other novel indications)
$
17,600

 
$
—

 
$
—

 
$
—

 
$
17,600

EVOMELA IPR&D
7,700

 
—

 
—

 
—

 
7,700

BELEODAQ distribution rights
25,000

 
(2,812
)
 
—

 
—

 
22,188

MARQIBO distribution rights
26,900

 
(8,544
)
 
—

 
—

 
18,356

FOLOTYN distribution rights
118,400

 
(29,474
)
 
—

 
—

 
88,926

ZEVALIN distribution rights – U.S.
41,900

 
(30,608
)
 
—

 
—

 
11,292

ZEVALIN distribution rights – Ex-U.S.
23,490

 
(12,632
)
 
(4,353
)
 
—

 
6,505

FUSILEV distribution rights
16,778

 
(9,618
)
 
—

 
(7,160
)
 
—

FOLOTYN out-license
27,900

 
(9,109
)
 
—

 
(1,023
)
 
17,768

Total intangible assets
$
305,668

 
$
(102,797
)
 
$
(4,353
)
 
$
(8,183
)
 
$
190,335
Estimated Intangible Asset Amortization Expense
Estimated intangible asset amortization expense for the remainder of 2016 and the five succeeding fiscal years and thereafter is as follows:

Years Ending December 31,
 
Remainder of 2016
$
18,017

2017
24,023

2018
24,023

2019
21,417

2020
16,113

2021
14,634

2022 and thereafter
48,926

 
$
167,153
Schedule of Goodwill
“Goodwill” is comprised of the following:
 
March 31, 2016
 
December 31, 2015
Acquisition of Talon (MARQIBO rights)
$
10,526

 
$
10,526

Acquisition of ZEVALIN Ex-U.S. distribution rights
2,525

 
2,525

Acquisition of Allos (FOLOTYN rights)
5,346

 
5,346

Foreign currency exchange translation effects
(353
)
 
(437
)
Goodwill
$
18,044

 
$
17,960
Summary of Other Assets
“Other assets” are comprised of the following: 
 
March 31, 2016
 
December 31, 2015
Equity securities and secured promissory note - CASI (see Note 10)*
$
7,520

 
$
6,689

Supplies and deposits**
1,165

 
185

2018 Convertible Notes issuance costs (excluding current portion)***
—

 
—

Executive officer life insurance – cash surrender value
9,651

 
9,181

Inventories - non-current portion
6,923

 
3,156

Other miscellaneous assets
45

 
—

Other assets
$
25,304

 
$
19,211


* These equity securities were excluded from “marketable securities” (see Note 3(a)) due to our intent to hold these securities for at least one year beyond March 31, 2016, as discussed in Note 10. Unrealized gains from these equity securities were recognized through “unrealized gain on available-for-sale securities" within the Condensed Consolidated Statements of Comprehensive Loss, and were $1.4 million for the three months ended March 31, 2016.

** Of this balance at March 31, 2016, $1.0 million relates to ZEVALIN inventories that we intend to consume in research and development activities in future periods as part of our new contract manufacturer validation process. Accordingly, we have presented this value within "other assets" rather than "inventories" due to our present intention for these units.

*** Beginning January 1, 2016, our debt issuance costs (current and non-current portions) were retrospectively reclassified from “prepaid expenses and other assets” and "other assets" to a reduction of the carrying amount of “convertible senior notes” (i.e., contra-liability - see Note 14) within our accompanying Consolidated Balance Sheets, in accordance with ASU 2015-03. These amounts were $2.0 million and $2.2 million (including current and non-current portions) as of March 31, 2016 and December 31, 2015, respectively.
Schedule of Accounts Payable and Other Accrued Liabilities
“Accounts payable and other accrued liabilities” are comprised of the following:
 
March 31, 2016
 
December 31, 2015
Trade accounts payable and other accrued liabilities
$
31,922

 
$
26,684

Accrued rebates
6,978

 
18,166

Accrued product royalty
4,076

 
4,908

Allowance for returns
1,429

 
1,394

Accrued data and distribution fees
1,126

 
1,830

Accrued GPO administrative fees
521

 
1,058

Accrued inventory management fee
210

 
498

Allowance for chargebacks
1,241

 
2,001

Accounts payable and other accrued liabilities
$
47,503

 
$
56,539
Schedule of Amounts Presented in Accounts Payable and Other Accrued Liabilities
Amounts presented within “accounts payable and other accrued liabilities” in the accompanying Condensed Consolidated Balance Sheets specifically for gross-to-net ("GTN") estimates (see Note 2(i)) are as follows:

Rebates and
Chargebacks
 
Data and
Distribution,
GPO Fees, and
Inventory
Management
Fees
 
Returns
Balance as of December 31, 2014
$
45,822

 
$
8,284

 
$
1,135

Add: provisions
75,498

 
15,928

 
1,486

(Less): credits or actual allowances
(101,153
)
 
(20,826
)
 
(1,227
)
Balance as of December 31, 2015
20,167

 
3,386

 
1,394

Add: provisions
19,952

 
2,227

 
590

(Less): credits or actual allowances
(31,900
)
 
(3,755
)
 
(555
)
Balance as of March 31, 2016
$
8,219

 
$
1,858

 
$
1,429
Deferred Revenue, by Arrangement, Disclosure
Deferred revenue (current and non-current) is comprised of the following:

March 31, 2016
 
December 31, 2015
Mundipharma deferred revenue (see Note 11)
$
2,472

 
$
—

FUSILEV deferred revenue*
—

 
6,083

Dr. Reddy's out-license (see Note 16(b)(iii))
436

 
430

Deferred revenue
$
2,908

 
$
6,513

* In the third quarter 2015, we deferred revenue recognition related to certain FUSILEV product shipments that did not meet our revenue recognition criteria (see Note 2(i)(a)), aggregating $9.9 million. Specifically, this deferral resulted from our inability to concurrently estimate future rebate values (with requisite precision) offered to our customers in order to compete with generic products. During the fourth quarter of 2015, we recognized $3.8 million for these third quarter shipments, and $6.1 million remained deferred as of December 31, 2015. In the first quarter 2016, this $6.1 million of deferred revenue was recognized in full.
Summary of Other Long-Term Liabilities
Other long-term liabilities are comprised of the following:
 
March 31, 2016
 
December 31, 2015
Accrued executive deferred compensation
$
7,117

 
$
6,458

Deferred rent (non-current portion)
235

 
248

Clinical study holdback costs, non-current
19

 
—

Other tax liabilities
738

 
738

Other long-term liabilities
$
8,109

 
$
7,444